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H epatocellular carcinoma (HCC) is the sixth-most common neoplasm and the third-most frequent 
cause of cancer death.  More than 700,000 HCC patients 
are newly diagnosed globally each year [1].  More 
patients are being diagnosed in the early stage thanks to 
the accumulation of knowledge about risk factors and 
the increasing prevalence of HCC surveillance.  The 
Japanese Clinical Practice Guidelines recommends 
radiofrequency ablation (RFA) or surgical resection for 
the treatment of early-stage HCC.  However,  surgical 
liver resection carries serious risks,  such as deteriora-
tion of liver function.
RFA is thought to be an effective treatment because 
of its high tumor control rate and low invasiveness.  The 
survival rates of patients who achieve complete ablation 
are comparable to those in patients resected by surgery 
[2 , 3].  In addition,  RFA combined with TACE has been 
Acta Med.  Okayama,  2018
Vol.  72,  No.  1,  pp.  47-52
CopyrightⒸ 2018 by Okayama University Medical School.
http ://escholarship.lib.okayama-u.ac.jp/amo/Original Article
Transcatheter Arterial Chemoembolization to Reduce Size of  
Hepatocellular Carcinoma before Radiofrequency Ablation
Soichiro Akoa,  Shinichiro Nakamuraa,  Kazuhiro Nousoa,b＊,  Chihiro Dohia,   
Nozomu Wadaa,  Yuki Morimotoa,  Yasuto Takeuchia,  Tetsuya Yasunakaa,   
Kenji Kuwakia,  Hideki Onishia,  Fusao Ikedaa,  Hidenori Shirahaa,   
Akinobu Takakia,  and Hiroyuki Okadaa
aDepartment of Gastroenterology and Hepatology,  Okayama University Graduate School of Medicine,   
Dentistry and Pharmaceutical Sciences,  Okayama 700-8558,  Japan,   
bDepartment of Gastroenterology,  Okayama City Hospital,  Okayama 700-8557,  Japan
Transcatheter arterial chemoembolization (TACE) is often performed before radiofrequency ablation (RFA) for 
the treatment of early-stage hepatocellular carcinoma (HCC).  TACE prior to RFA can expand the ablated area 
and reduce the tumor size,  facilitating complete ablation.  However,  the factors correlated with size reduction 
remain uncertain.  The aim of this study was to identify the factors associated with size reduction by TACE and 
develop a formula to predict the reduction rate.  A total of 100 HCC patients treated with TACE followed by RFA 
at least 20 days later were enrolled.  The tumor size was measured at the time of TACE and RFA,  and correla-
tions between the reduction rate and 13 clinical factors were examined.  A formula to predict the reduction rate 
was built using the factors obtained by the analysis.  Reduction in the tumor size was observed in 69 nodules,  
and the median reduction rate was 16.2%.  A multivariate regression analysis revealed that a large tumor size 
(p< 0.01) and a long interval between the therapies (p= 0.01) were factors for a high tumor reduction rate,  with 
tumor size more strongly related to the degree of reduction.  A size reduction of more than 10% can be expected 
by waiting 20 days after TACE when the size of the tumor at TACE is over 25 mm in diameter.  The tumor size at 
TACE and the interval between TACE and RFA were closely correlated with HCC size reduction by TACE.
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reported to contribute to an improved recurrence-free 
survival rate and treatment time [4-10].  The advantages 
of TACE are tumor necrosis by chemotherapy and 
occlusion of the feeding artery flow by embolization,  
which lead to tumor reduction or extension of the abla-
tion area due to less heat loss by convection [11].  In 
most previous reports on combination therapy,  the 
interval between TACE and RFA has been within 2 
weeks [5 , 8 , 12-15].  While prolongation of the interval 
might lead to a reduction in the size of HCC,  no studies 
have examined the effect of a longer interval between 
the two therapies.
In this study,  we analyzed the factors correlated with 
the reduction in the size of HCC after TACE and tried to 
predict the reduction rate.
Methods
Patients. This retrospective study was conducted 
at the Department of Gastroenterology and Hepatology,  
Okayama University,  Japan.  From January 2001 to 
December 2014,  a total of 1358 HCCs were treated 
with combination therapy of TACE and RFA.  The diag-
nosis of HCC was confirmed pathologically or based on 
the findings of typical radiological features using con-
trast-enhanced computed tomography (CT) or dynamic 
magnetic resonance imaging (MRI) [16].
The eligibility criteria were as follows: a single tumor 
≤ 5 cm in diameter,  or 3 or fewer nodules ≤ 3 cm in 
diameter; a Child-Pugh grade A or B; sufficient iodized 
oil accumulation at the lesions treated with TACE;  
lesion visibility on abdominal ultrasonography (AUS);  
and RFA performed more than 20 days after TACE.  All 
patients in this study provided informed consent for the 
use of their clinical data in the analysis.  This study was 
approved by our institutional review board (No. 1609-
501) and was conducted according to the Helsinki Dec-
laration.  Ulti mately,  100 patients were enrolled in this 
study (Fig. 1).
TACE procedure. TACE was performed using the 
Seldinger technique followed by arterial embolization.  
After introducing a 3- or 4-Fr catheter through the fem-
oral artery,  hepatic arteriography and superior mesen-
teric arterial portovenography were performed to eval-
uate portal flow and the location of the tumors.  When 
the portal flow was deemed sufficient,  a 1.8- or 2.0-Fr 
microcatheter was placed in the feeding arteries.  An 
emulsion consisting of 30-60 mg of epirubicin (Kyowa-
Hakko,  Tokyo,  Japan) and 2-6 mL of iodized oil 
(Lipiodol Ultrafluid; Terumo,  Tokyo,  Japan) was 
injected into the artery supplying blood to the tumor,  
followed by embolization with 1-mm gelatin sponge 
particles (Gelfoam; Nihonkayaku,  Tokyo,  Japan).  
After embolization,  CT angiography was performed to 
determine the extent of vascular occlusion.
Measurement of tumor size. We measured the 
maximum tumor size just before TACE and RFA.  
Before TACE,  we measured the diameter of the tumor 
on CT during hepatic arteriography (CTHA).  At RFA 
we measured the diameter of the tumor by AUS.  After 
treatment,  all patients received follow-up every 3-6 
months during follow up period by blood testing and 
dynamic contrast-enhanced CT or AUS.
Statistical analysis. The following parameters 
were used to analyze the factors involved in tumor 
reduction: age,  sex,  viral markers (hepatitis B virus 
surface antigen and hepatitis C virus antibody),  Child-
Pugh grade,  size of tumors,  number of tumors,  inter-
val between TACE and RFA,  total bilirubin and albu-
min (Alb) levels,  platelet (PLT) count,  prothrombin 
time (PT),  and levels of α-Fetoprotein (AFP) and 
des-gamma-carboxy prothrombin (DCP).  Cut-off val-
ues were defined by median or standard values.  The 
baseline characteristics are presented as medians and 
ranges.  The change in the tumor size between therapies 
was analyzed by a paired t-test.  The least squares 
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Fig. 1　 Enrollment process of patients.  1358 HCCs were treated 
with TACE and RFA in Okayama University Hospital from January 
2001 to December 2014.  One hundred patients were satisﬁed with 
the eligibility criteria.
method was performed to analyze the factors involved 
in tumor reduction.
Variables with a p-value < 0.05 in a univariate com-
parison were subjected to a multivariate regression 
analysis.  The predictive tumor reduction rate was esti-
mated using a multivariate regression model.  All of the 
significance tests were two-sided,  and differences with 
a p-value < 0.05 were considered significant.  Statistical 
analyses were performed using JMP 11.0 (SAS Institute,  
Cary,  NC,  USA).
Results
Factors for tumor reduction after TACE. The 
patient characteristics are shown in Table 1.  The median 
tumor diameter at TACE was 17.8 mm (range,  3.8-
42.5 mm),  and the median interval between TACE and 
RFA was 42 days (range,  21-643 days).  The median 
reduction rate was 16.2%.  Tumor size was reduced,  
unchanged,  and increased in 69%,  3%,  and 28% of the 
patients,  respectively (Fig. 2).  Univariate analysis 
revealed that the factors related to tumor reduction after 
TACE were the tumor size at TACE and the interval 
between the therapies (p < 0.01 and p = 0.02,  respec-
tively) (Table 2).  A multivariate analysis with the fac-
tors showing a p-value < 0.05 in the univariate analysis 
revealed that both the tumor size at TACE and the 
interval between the therapies remained significant fac-
tors in the multivariate analysis (p < 0.01 and p = 0.01,  
respectively).
Construction of a formula predicting tumor reduc-
tion rate. To predict the tumor reduction rate,  we 
constructed a formula based on the results of the least-
square method using the 2 factors above,  as follows:
Tumor reduction rate (%) =[tumor size at TACE 
(mm) × 1.1] + [interval between the therapies (days) 
× 0.06] − 17
A clear correlation was observed between the mea-
sured reduction rate and the predictive reduction rate 
(Fig. 3,  R2 = 0.23,  p < 0.001).  Table 3 shows the calcu-
lated reduction rate.  The reduction rate largely 
depended on the tumor size at TACE.  For initially 
small tumors ( ≤ 20 mm in diameter),  the size reduction 
rate was within 10%.  Conversely,  over 10% size reduc-
tion was expected for larger tumors ( ≥ 25 mm) over 20 
days after TACE.  The 1-year local recurrence rate after 
the combination therapy was 3.2%.
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Table 1　 Clinical proﬁle of 100 patients
Characteristic Value
Age (years old) 70.5 (28-85)
Sex (male/female) 77/23
Etiology (HBV/HCV/HBV＋HCV/others) 12/79/1/8
Child-Pugh class (A/B) 76/24
Tumor size at TACE (mm) 17.8 (3.8-42.5)
Tumor number (1/≥2) 78/22
Interval between therapies (days) 42 (21-643)
AST (IU/L) 47 (18-165)
ALT (IU/L) 39 (11-201)
Total bilirubin (mg/dL) 0.76 (0.3-2.4)
Albumin (g/dL) 3.6 (2-4.5)
Prothrombin time (%) 93 (59-130)
PLT (/µL) 10.9 (2.8-32.9)
AFP (ng/mL) 16.8 (2-5131)
DCP (mAU/mL) 59 (8.2-451)
Median (range)
ALT,  alanine aminotransferase; AST,  aspartate aminotransferase;  
PLT,  platelet; AFP,  alpha-fetoprotein; DCP,  des-gamma-carboxy 
prothrombin.
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45
40
35
30
25
20
15
10
5
Tu
m
or
 s
iz
e 
(m
m
)
At TACE At RFA
Fig. 2　 Change in tumor size between therapies.  Tumor size was 
reduced,  unchanged and increased in 69%,  3%,  and 28% of the 
patients,  respectively.  The median reduction rate in all nodules 
was 16.2% (p＜0.05).
Discussion
Our analysis showed that tumor reduction after 
TACE was observed in 69% of the nodules,  and the 
median reduction rate was 16.2%.  The factors related to 
tumor reduction were tumor size at TACE and the 
interval between TACE and RFA.  Tumor size at TACE 
was particularly strongly related to the reduction.  If the 
tumor size was ≥ 25 mm,  the predicted reduction rate 
was over 10% at RFA.
One of the mechanisms behind this reduction is the 
level of development of tumor vessels.  Bigger tumors 
have more abundant blood flow,  which facilitates the 
dispersal of anticancer agents or gelatin sponge parti-
cles.  Consequently,  larger tumor size leads to more 
effective necrosis measures and subsequent tumor 
reduction.  In contrast,  the relationship between the 
degree of tumor reduction and the interval between 
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Table 2　 Factors related with size reduction
Number of
patients (n)
Tumor reduction
rate (%)
(median,  range)
Univariate
p-value
Multivariate
p-value
Age
≥70 54 11.1 (－37.0-41.4)
0.16
＜70 46 6.6 (－52.7-50.3)
Sex
male 77 8.0 (－52.7-50.3)
0.47female 23 13.9 (－24.8-39.5)
HCV
＋ 80 8.0 (－42.5-50.3)
0.25
－ 20 9.1 (－52.7-50)
HBV
＋ 13 13.9 (－52.7-25.6)
0.19
－ 87 8.0 (－42.5-50.3)
Child-Pugh grade
A 76 10.3 (－52.7-50.3)
0.82B 24 6.6 (－35.5-39.5)
Tumor size at TACE
≥17 mm 57 16.0 (－15.2-50)
＜0.01 ＜0.01
＜17 mm 43 0 (－52.7-50.3)
Interval between ≥40 days 51 15.0 (－52.7-50.3)
0.02 0.01TACE and RFA ＜40 days 49 1.7 (－42.5-39.5)
T-bil (mg/dl)
≥1.0 28 7.9 (－35.7-50.3)
0.96
＜1.0 72 10.1 (－52.7-50)
Albumin (g/dL)
≥3.5 59 13.9 (－52.7-50)
0.54
＜3.5 41 6.0 (－42.5-50.3)
Prothrombin time (%)
≥100 36 9.1 (－32-36.5)
0.90
＜100 64 8.0 (－52.7-50.3)
PLT (/µL)
≥150000 32 4.8 (－20.8-36.5)
0.80
＜150000 68 11.1 (－52.7-50.3)
AFP (ng/mL)
≥20 48 5.7 (－42.5-39.3)
0.16
＜20 52 14.4 (－52.7-50.3)
DCP (mAU/mL)
≥50 52 9.0 (－37.0-50.3)
0.21
＜50 47 8 (－52.7-50)
HCV+,  positive for hepatitis C virus antibody; HBV+,  positive for hepatitis B virus antigen; PLT,  platelet count; AFP,  alpha-fetopro-
tein; DCP,  des-gamma-carboxy prothrombin.
therapies was relatively weak.  No significant further 
tumor reduction was achieved with an interval over 20 
days.  Indeed,  the difference in the predicted size reduc-
tion between 20 days and 80 days after TACE was only 
about 1 mm.  This implies that most tumor reduction 
mainly occurs within the first 20 days after TACE.  At 
our institute,  RFA is usually performed 7 days after 
TACE.  We preliminary measured the size of tumors 
treated by TACE and RFA at a 7-days interval (n = 10).  
Tumor size reduction was observed in only 4 patients,  
and the median change rate of all 10 patients was a 2.5% 
increase.  Therefore,  the bulk of the reduction in patients 
with at least a 20-day interval may have occurred 
between 7 and 20 days after TACE.  Altogether,  our 
data suggest that 20 days might be a sufficient interval 
for tumor reduction.
Although a greater tumor reduction can be expected 
by extending the interval,  waiting too long might 
increase the risk of tumor re-enlargement and local 
recurrence.  In the present study,  however,  over two-
thirds of the tumors achieved a size reduction following 
TACE,  and the 1-year local recurrence rate was 3.2%,  
which was as low as that found in our previous report in 
which most patients were treated by RFA at 7 days after 
TACE [17].  These results indicated that a greater-than-
20-day interval did not increase the risk of local recur-
rence,  so long as sufficient iodized oil accumulation 
during TACE was achieved.  Obtaining these promising 
results requires the accumulation of iodized oil,  since 
insufficient iodized oil accumulation is a risk factor of 
recurrence after TACE,  as we reported previously [18].
In most previous studies,  RFA has been performed 
about one week after TACE.  In the present study,  we 
found that small HCCs ( ≤ 20 mm in diameter) did not 
shrink in size,  regardless of the interval after TACE; in 
the case of small lesions,  then,  it is therefore better to 
perform RFA soon after TACE,  as in most studies.  
Conversely,  waiting somewhat longer might be better 
for HCCs ≥ 25 mm,  as we can expect substantial size 
reduction,  thereby facilitating ablation of the tumor 
without increasing the risk of local recurrence.
Several limitations associated with the present study 
warrant mention.  First,  this is a retrospective study,  
and the number of patients who underwent TACE and 
RFA with a long interval between them was limited.  
Second,  patient selection bias might exist.  We usually 
have a long interval between TACE and RFA in the case 
of patients who need physical recovery after TACE.  So,  
a patient’s condition might be related to the change of 
tumor size.  Third,  in this study we measured the tumor 
size based on CT and AUS scans.  The difference in the 
modality may have influenced the perceived tumor size.  
Finally,  we did not examine the degree of tumor reduc-
tion in patients who were treated by RFA between 7 and 
20 days after TACE,  which might be when the bulk of 
tumor reduction occurs.
In conclusion,  the tumor size at TACE and the 
interval between TACE and RFA were correlated with 
tumor reduction after TACE.  In particular,  large 
tumors ( ≥ 25 mm) had a potential size reduction of 
≥ 10% if RFA was delayed slightly after TACE,  without 
increasing the local recurrence rate.  These findings 
suggest that waiting 7-20 days after TACE might be a 
useful strategy for RFA when treating large tumors.
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Table 3　 Expected reduction of tumor size after TACE
Tumor
diameter
at TACE
Days after TACE
20 40 60 80
15 mm 1% (0.1 mm) 2% (0.3 mm) 3% (0.5 mm) 4% (0.6 mm)
20 mm 6% (1.2 mm) 7% (1.5 mm) 9% (1.7 mm) 10% (2.0 mm)
25 mm 11% (2.9 mm) 13% (3.2 mm) 14% (3.5 mm) 15% (3.8 mm)
30 mm 17% (5.2 mm) 18% (5.5 mm) 20% (5.9 mm) 21% (6.2 mm)
35 mm 23% (7.9 mm) 24% (8.4 mm) 25% (8.8 mm) 26% (9.2 mm)
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Fig. 3　 Relationship between the measured reduction rate and the 
predictive reduction rate.  A clear correlation was observed between 
the measured reduction rate and the predicted reduction rate.
References
 1. Ferlay J,  Shin HR,  Bray F,  Forman D,  Mathers C and Parkin DM:  
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 
2008.  Int J Cancer (2010) 127: 2893-2917.
 2. Huang GT,  Lee PH,  Tsang YM,  Lai MY,  Yang PM,  Hu RH,  
Chen PJ,  Kao JH,  Sheu JC,  Lee CZ and Chen DS: Percutaneous 
ethanol injection versus surgical resection for the treatment of small 
hepatocellular carcinoma: a prospective study.  Ann Surg (2005) 
242: 36-42.
 3. NʼKontchou G,  Mahamoudi A,  Aout M,  Ganne-Carrie N,  Grando V,  
Coderc E,  Vicaut E,  Trinchet JC,  Sellier N,  Beaugrand M and 
Seror O: Radiofrequency ablation of hepatocellular carcinoma:  
long-term results and prognostic factors in 235 Western patients 
with cirrhosis.  Hepatology (2009) 50: 1475-1483.
 4. Peng ZW and Chen MS: Transcatheter arterial chemoembolization 
combined with radiofrequency ablation for the treatment of hepato-
cellular carcinoma.  Oncology (2013) 84 Suppl 1: 40-43.
 5. Kim JW,  Kim JH,  Won HJ,  Shin YM,  Yoon HK,  Sung KB and 
Kim PN: Hepatocellular carcinomas 2-3 cm in diameter: transar-
terial chemoembolization plus radiofrequency ablation vs. radiofre-
quency ablation alone.  Eur J Radiol (2012) 81: e189-193.
 6. Xie H,  Wang H,  An W,  Ma W,  Qi R,  Yang B,  Liu C,  Gao Y,  Xu 
B and Wang W: The eﬃcacy of radiofrequency ablation combined 
with transcatheter arterial chemoembolization for primary hepato-
cellular carcinoma in a cohort of 487 patients.  PloS one (2014) 9:  
e89081.
 7. Morimoto M,  Numata K,  Kondou M,  Nozaki A,  Morita S and 
Tanaka K: Midterm outcomes in patients with intermediate-sized 
hepatocellular carcinoma: a randomized controlled trial for deter-
mining the eﬃcacy of radiofrequency ablation combined with tran-
scatheter arterial chemoembolization.  Cancer (2010) 116: 5452-
5460.
 8. Kim JW,  Shin SS,  Kim JK,  Choi SK,  Heo SH,  Lim HS,  Hur YH,  
Cho CK,  Jeong YY and Kang HK: Radiofrequency ablation com-
bined with transcatheter arterial chemoembolization for the treat-
ment of single hepatocellular carcinoma of 2 to 5 cm in diameter:  
comparison with surgical resection.  Korean journal of radiology:  
oﬃcial journal of the Korean Radiological Society (2013) 14: 626-
635.
 9. Kagawa T,  Koizumi J,  Kojima S,  Nagata N,  Numata M,  Watanabe 
N,  Watanabe T,  Mine T and Tokai RFASG: Transcatheter arterial 
chemoembolization plus radiofrequency ablation therapy for early 
stage hepatocellular carcinoma: comparison with surgical resec-
tion.  Cancer (2010) 116: 3638-3644.
10. Ni JY,  Liu SS,  Xu LF,  Sun HL and Chen YT: Meta-analysis of 
radiofrequency ablation in combination with transarterial chemoem-
bolization for hepatocellular carcinoma.  World J Gastroenterol 
(2013) 19: 3872-3882.
11. Kitamoto M,  Imagawa M,  Yamada H,  Watanabe C,  Sumioka M,  
Satoh O,  Shimamoto M,  Kodama M,  Kimura S,  Kishimoto K,  
Okamoto Y,  Fukuda Y and Dohi K: Radiofrequency ablation in the 
treatment of small hepatocellular carcinomas: comparison of the 
radiofrequency eﬀect with and without chemoembolization.  AJR 
Am J Roentgenol (2003) 181: 997-1003.
12. Peng ZW,  Zhang YJ,  Chen MS,  Xu L,  Liang HH,  Lin XJ,  Guo 
RP,  Zhang YQ and Lau WY: Radiofrequency ablation with or with-
out transcatheter arterial chemoembolization in the treatment of 
hepatocellular carcinoma: a prospective randomized trial.  J Clin 
Oncol (2013) 31: 426-432.
13. Cheng BQ,  Jia CQ,  Liu CT,  Fan W,  Wang QL,  Zhang ZL and Yi 
CH: Chemoembolization combined with radiofrequency ablation 
for patients with hepatocellular carcinoma larger than 3 cm: a ran-
domized controlled trial.  JAMA (2008) 299: 1669-1677.
14. Choe WH,  Kim YJ,  Park HS,  Park SW,  Kim JH and Kwon SY:  
Short-term interval combined chemoembolization and radiofrequency 
ablation for hepatocellular carcinoma.  World J Gastroenterol (2014) 
20: 12588-12594.
15. Sakurai M,  Okamura J and Kuroda C: Transcatheter chemo-embo-
lization eﬀective for treating hepatocellular carcinoma.  A histo-
pathologic study.  Cancer (1984) 54: 387-392.
16. Bruix J and Sherman M: American Association for the Study of 
Liver D: Management of hepatocellular carcinoma: an update.  
Hepatology (2011) 53: 1020-1022.
17. Toshimori J,  Nouso K,  Nakamura S,  Wada N,  Morimoto Y,  
Takeuchi Y,  Yasunaka T,  Kuwaki K,  Ohnishi H,  Ikeda F,  Shiraha 
H,  Takaki A and Yamamoto K: Local recurrence and complica-
tions after percutaneous radiofrequency ablation of hepatocellular 
carcinoma: a retrospective cohort study focused on tumor location.  
Acta Med Okayama (2015) 69: 219-226.
18. Kinugasa H,  Nouso K,  Takeuchi Y,  Yasunaka T,  Onishi H,  
Nakamura S,  Shiraha H,  Kuwaki K,  Hagihara H,  Ikeda F,  Miyake 
Y,  Takaki A and Yamamoto K: Risk factors for recurrence after 
transarterial chemoembolization for early-stage hepatocellular car-
cinoma.  J Gastroenterol (2012) 47: 421-426.
52 Ako et al. Acta Med.  Okayama　Vol.  72,  No.  1
